This article is more than 5 years old. Information may no longer be current.

PrEP reduced risk for HIV among uninfected heterosexuals

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Results from two new trials released today indicate that once-daily ART reduced the risk for HIV infection among uninfected men and women exposed to HIV through heterosexual sex, according to a CDC press release.

“These are exciting results for global HIV prevention. We now have findings from two studies showing that PrEP can work for heterosexuals, the population hardest hit by HIV worldwide,” Kevin Fenton, MD, Infectious Disease News Editorial Board member and director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention said in the press release. “Taken together, these studies provide strong evidence of the power of this prevention strategy.”

Data from the CDC’s TDF2 study conducted in collaboration with the Botswana Ministry of Health, indicated that once-daily tenofovir disoproxil fumerate in combination with emtricitabine (Truvada, Gilead) effectively reduced the risk for HIV infection by approximately 63% among uninfected heterosexual men and women.

Preliminary findings from the second study released today — Partners PrEP study — indicate that two different regimens, tenofovir (Viread, Gilead) and tenofovir disoproxil fumerate plus emtricitabine, both reduced HIV transmission among couples in which one partner is infected with HIV and the other is not. This trial was halted early due to strong evidence of effectiveness of the drugs.

“The CDC study findings were scheduled to be released next week at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome by the CDC principal investigator, Michael C. Thigpen, MD, however, due to the unexpected release of the Partners PrEP data today, CDC is releasing the TDF2 results now, to ensure that all emerging trial data are concurrently available to fully inform public health and policy discussions moving forward. The results will still be presented and discussed at the IAS 2011 conference on Wednesday, July 20,” CDC officials wrote in the press release.

Follow InfectiousDiseaseNews.com on Twitter.